Gong XZ, Duan YR, Zheng JL, Wang YR, Wang GH, Norgren S, et al. Nephroprotective effects of N-acetylcysteine amide against contrast-induced nephropathy through upregulating thioredoxin-1, inhibiting ASK1/p38MAPK pathway, and suppressing oxidative stress and apoptosis in rats. Oxid Med Cell Longev 2016;2016:8715185.

Gong XZ, Celsi G, Carlsson K, Norgren S, Chen M. N-acetylcysteine amide protects renal proximal tubular epithelial cells against iohexol-induced apoptosis by blocking p38 MAPK and iNOS signaling. Am J Nephrol 2010;31:178–188.

Geenen RW, Kingma HJ, van der Molen AJ. Contrastinduced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging 2013;4:811–820.

Abu Jawdeh BG, Leonard AC, Sharma Y, Katipally S, Shields AR, Alloway RR, et al. contrast-induced nephropathy in renal transplant recipients: a single center experience. Front Med (Lausanne) 2017;4:64.

Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011;12:2527–2541.

Chong E, Shen L, Poh KK, Tan HC. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention. Singapore Med J 2012;53:164–169.

Schilp J, de Blok C, Langelaan M, Spreeuwenberg P. Guideline adherence for identification and hydration of highrisk hospital patients for contrast-induced nephropathy. BMC Nephrol 2014;15:2.

Che ML, Yan YC, Zhang Y, Gu Y, Wang NS, Chen N, et al. Analysis of drug-induced acute renal failure in Shanghai. Natl Med J China (Chin) 2009;89:744–749.

Yuan Y, Qiu H, Hu X, Luo T, Gao X, Zhao X, et al. Predictive value of inflammatory factors on contrast-induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. Clin Cardiol 2017; May 19. doi: 10.1002/clc.22722. [Epub ahead of print]

Gong XZ, Wang Q, Tang XC, Wang YR, Fu D, Lu HY, et al. Tetramethylpyrazine prevents contrast-induced nephropathy by inhibiting p38 MAPK and FoxO1 signaling pathways. Am J Nephrol 2013;37:199–207.

Gong XZ, Wang YR, Fu D, Tang XC, Wang YR, Wang GH, et al. Research on Radix et Rhizoma Rhei-Rhizoma Ligustici Chuanxiong restraining renal tubular epithelial cell apoptosis in contrast-induced nephropathy rats. Shanghai J Tradit Chin Med (Chin) 2013;47:69–71.

Gong XZ, Wang YR, Fu D, Tang XC, Wang YR, Wang GH, et al. Effects of Zhi Dahuang-Chuan Xiong drug pair on tubular epithelial cell apoptosis in contrast-induced nephropathy rats. Chin J Integr Tradit West Nephrol (Chin) 2012;13:675–677.

Gong XZ, Wang YR, Wang GH, Fu D, Wang Q, Tang XC, et al. TMP inhibited apoptosis of tubular epithelial cells in contrast-induced nephropathy rats. Beijing Med J (Chin) 2013;35:131–133.

Men WJ, Ding ZM. Effect of Uremic Granule on renal function and microinflammation in patients with chronic renal failure. Chin J Intern Med (Chin) 2016;33:201–202.

Wang XC, Liu CH, Wu C. Effects of colonic dialysis combined with Uremic Clearance Granule retention-enema on patients with chronic renal failure. J Pract Med (Chin) 2012;28:2528–2530.

Ding WF, Zhong AM, Wang JY, Song L, Chen H. Renal protective effects and mechanism of Uremic Clearance Granule on contrast-induced nephropathy. Chin J Integr Tradit West Nephrol (Chin) 2014;15:612–614.

Lian JP, Han S, Fang ZY, Li XC, Zuo Y. Effects of Shenkang Injection on chronic renal failure: a meta-analysis. Chin Tradit Patent Med (Chin) 2015;37:1677–1682.

Wang XD, Shen JP, Lou B. Observation on the effect of Shenkang Injection on preventing contrast-induced nephropathy after senile coronary heart disease interventional surgery. J Nanjing Univ Tradit Chin Med (Chin) 2013;29:426–428.

Zhang W. The clinical study of Danhong Injection combined with edaravone in the treatment of acute ischemic stroke. Chin J Prim Med Pharm (Chin) 2017;24:1050–1053.

Leng Q, Dai R, Liu YH. Influence of Danhong Injection on the microcirculation state related indexes of patients with myocardial infarction. J Clin Med Pract (Chin) 2017;23:6–8.

Liu JY, Li QH, Yin JF. Clinical efficacy and prevention of Danhong Injection in contrast-induced nephropathy (CIN) in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). Jilin Med (Chin) 2013;34:6474–6475.

Qi CX, Wu W, Zhu QM, Wang CC, Qin LJ, Xu YT. Systematic review and Meta-analysis of Danhong Injection combined with hydration in the prevention of contrast-induced nephropathy. Chin J Integr Med Cardio- Cerebrovasc Dis (Chin) 2017;15:570–573.

Zhao CX, Jin HX. Progress of pharmacological action mechanism and clinical application of salvianolic acid. Hebei Med (Chin) 2017;39:294–299.

Hua JY, Sun Q, Jiang XH, He YZ, Lv SM. Protective effect of salvianolate on contrast-induced nephropathy after coronary interventional therapy. Zhejiang Med (Chin) 2012;34:1883–1885.

Xu WY, Li P, Li ZX, Zhao YM, Wang ZD, Chen J. Effects of the alprostadil combined with salvianolate on renal function in patients who received PCI. Chin J Evid Based Cardiovasc Med (Chin) 2017;9:277–279.

Huang J, Yuan M, Ma J, Liu R, Dong Z, Zhao G, et al. Protective effects of salvianolate on contrast-induced nephropathy after primary percutaneous coronary intervention: a prospective multicenter randomized controlled trial. Cardiology 2017;138:169–178.